Dana-Farber/Harvard Cancer Center

Joint Symposium of the Dana-Farber/Harvard Cancer Center Programs in Breast and Gynecologic Cancers

March 4, 2016

GENETICS AND GENOMICS

1. Genome-scale Screening for New Oncogenes Allison P Clark, Manish Neupane, Dave E Hill, Marc Vidal and Daniel P Silver

2. Integrated analysis of mRNA, copy number and proteomics profiles of TCGA high-grade serous ovarian cancer reveals new markers of prognosis. Aedin Culhane

3. The genomic evolution of endometrial carcinoma progression and abdominopelvic metastasis. William J. Gibson, Erling A. Hoivik, Mari K. Halle, Amaro Taylor-Weiner, Andrew D. Cherniack, Anna Berg, Frederik Holst, Travis I. Zack, Henrica M. J. Werner, Kjersti M. Staby, Mara Rosenberg, Ingunn M Stefansson, Kanthida Kusonmano, Aaron Chevalier, Karen K. Mauland, Jone Trovik, Camilla Krakstad, Marios Giannakis, Eran Hodis, Kathrine Woie, Line Bjorge, Olav K. Vintermyr, Jeremiah Wala, Michael S Lawrence, Gad Getz , Scott L. Carter , Rameen Beroukhim , Helga B. Salvesen

4. Identification of subtype-specific gene regulation in high-grade serous ovarian cancer Kuijjer ML, Glass K, Quackenbush J

5. Feasibility and efficacy of a precision treatment approach for triple-negative breast cancer in mouse models Hui Liu, Charlie Murphy, Florian Karreth, Kang Kang Yang, Olivier Elemento, Gerburg M. Wulf, Lewis C. Cantley

6. Analysis of Resistance to the Combination of a PI3K- and Parp-Inhibitor Using a Genomic Sequencing Approach Sheida Nabavi, Ashish Juvekar, Nicholas Wang, Lewis C. Cantley, and Gerburg Wulf 7. Understanding the genomic underpinnings of breast cancer in young women C Oh, N Wagle, E Morgan, B Larsen1, K Ruddy, T Cederroth, E Brachtel, L Schapira, SE Come, V Borges, E Warner, E Winer, LC Collins and A Partridge

8. Epigenomic changes induced by PI3K/AKT inhibitors are mediated by the dephosphorylation of the H3K4 demethylase KDM5A Spangle, JM, Dreijerink, KM, Groner, AC, Cheng, H, Ohlson C, Reyes, J, Lin, CY, Bradner, J,Zhao, JJ, Roberts, TM, and Brown, M.

9. An open-reading frame overexpression screen to identify genes mediating cisplatin and paclitaxel response in high-grade serous ovarian cancer cell lines. Elizabeth Stover, Cory Johanessen, Federica Piccioni, Mukta Bagul, Ursula Matulonis, Levi Garraway

10.Mechanisms of resistance (MoR) to DNA damaging therapy in BRCA1/2- deficient metastatic breast cancer (MBC) Adrienne G. Waks, Ofir Cohen, Karla Helvie, Max Lloyd, Lori Marini, Coyin Oh, Nelly Oliver, Neal I. Lindeman, Ursula Matulonis, Ian Krop, Levi A. Garraway, Eric P. Winer, Nancy U. Lin, Nikhil Wagle

11.BCL6 and MYC cooperate to promote high grade serous ovarian cancer Sarah R. Walker, Marieke Kuijjer, Yixi Zhang, John Quackenbush, and David A. Frank

12.CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer Yubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, Brian J. Abraham, Tong Ihn Lee, Shaozhen Xie, Haluk Yuzugullu, Thanh Von, Heyuan Li, Ziao Lin, Daniel G. Stover, Elgene Lim, Zhigang C. Wang, J. Dirk Iglehart, Richard A. Young, Nathanael S. Gray and Jean J. Zhao

13.Chromosomal scars and response to PARP inhibitor-based therapy in ovarian caner Zhigang C. Wang, Nicolai Juul Birkbak, William T. Barry, Thomas M. Roberts, Eric P. Winer, J Dirk Iglehart, Ursula A. Matulonis, and Joyce F. Liu

14.Tumor-Stroma Cross-Talk in High Grade Serous Ovarian Cancer Oana A. Zeleznik, Shelley S. Tworoger, Aedin C. Culhane

CLINICAL AND TRANSLATIONAL STUDIES

15.The combination of bazedoxifene and palbociclib in the treatment of ER+ breast cancer Macintosh Cornwell, Matthew Pun, Mai Nguyen, Gilles Buchwalter, Myles Brown, Rinath Jeselsohn 16.Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts). Antonio Di Meglio, Nancy U Lin, Rachel A Freedman, William T Barry, Eric P Winer, Ines Vaz-Luis

17. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti- angiogenic Agents for Triple Negative Breast Cancer Peng Guo, Jiang Yang, Marsha A. Moses and Debra T. Auguste 18. Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models Claudia Iavarone, Ioannis Zervantonakis, Laura Selfors, Hsing-Yu Chen, Sangeetha S. Palakurthi, Joyce Liu, Ursula Matulonis, Ronny Drapkin, Gordon Mill, Joel Leverson, Deepak Sampath, and Joan S. Brugge

19.In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts Panagiotis A. Konstantinopoulos, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Joyce F. Liu, Naveen Kommajosyula, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis

20.MicroRNA profiling to identify novel determinants of platinum resistance in BRCA1/2-mutated high grade serous ovarian cancer Khyati Meghani, Yizhou He, Elizabeth Swisher, Ursula Matulonis, Panagiotis A Konstantinopoulos and Dipanjan Chowdhury

21.Orthotopic PDX models of HER2+ breast cancer brain metastases facilitate discovery of a therapeutic strategy yielding durable remissions Jing Ni, Shakti H. Ramkissoon, Shaozhen Xie, Shom Goel, Daniel G. Stover, Hanbing Guo, Victor Luu, Eugenio Marco, Lori A. Ramkissoon, Yun Jee Kang, Marika Hayashi, Quang-De Nguyen, Azra H. Ligon, Rose Du, Elizabeth B. Claus, Brian M. Alexander, Guo-Cheng Yuan, Zhigang C. Wang, J. Dirk Iglehart, Ian E. Krop, Thomas M. Roberts, Eric P. Winer, Nancy U. Lin, Keith L. Ligon, Jean J. Zhao

22.A Reversible Contraceptive that Protects the Ovarian Reserve During Chemotherapy. David Pépin, Motohiro Kano, Amanda Sosulski, Lihua Zhang, Fotini Nicolaou, Nicholas Nagykery, Guangping Gao, Patricia K. Donahoe

23.Cost-effectiveness of the Oncotype Dx DCIS Score for Guiding Treatment of Patients with Ductal Carcinoma In Situ Ann C. Raldow, MD MPH, David Sher, MD MPH, Aileen B. Chen, MD MPP, Abram Recht, MD, Rinaa S. Punglia, MD MPH 24.Immune Activation Signatures Identify a Subset of ER+ Breast Cancers with Increased Pathologic Complete Response to Neoadjuvant Chemotherapy Daniel G. Stover, Adrienne G. Waks, Sara M. Tolaney, Joan S. Brugge, Eric P. Winer, and Laura M. Selfors

25.Immunogenicity of clear cell ovarian cancer: association with ARID1A loss, microsatellite instability and endometriosis Kyle C. Strickland, Brooke E. Howitt, Scott Rodig, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

26.Nipple Changes During and After Pregnancy in Women who Have Undergone Nipple Sparing Mastectomy Rong Tang MD, Suzanne B. Coopey MD, Jennifer Plichta MD, Upahvan Rai, Amy S. Colwell MD, Michele A. Gadd MD, Michelle C. Specht MD, William G. Austen, Jr. MD, Barbara L. Smith MD, PhD

27.Factors associated with non-use of adjuvant trastuzumab in older patients with HER2-positive breast cancer: a population-based study Ines Vaz-Luis, Nancy U. Lin, Nancy L. Keating, William T. Barry, Joyce Lii, Harold J. Burstein, Eric P. Winer, Rachel A. Freedman

28.Neutralization of BCL2/XL enhances the cytotoxicity of T-DM1 in vivo. Jason J. Zoeller, Roderick T. Bronson, Deepak Sampath, Joel Leverson, Joan S. Brugge

RISK AND PREVENTION

29.QUALITY OF BREAST CANCER SCREENING IN BRAZIL: EXTERNAL ASSESSMENT FOR IMPROVING ACCESS AND QUALITY PROGRAM Mara Rejane Barroso Barcelos, Rita de Cássia Duarte Lima, Elaine Tomasi, Bruno Nunes, Suele Manjourany Silva Duro, Malgorzata Chalupowski, Timothy Rebbeck, Luiz Augusto Facchini

30.QUALITY OF CERVICAL CANCER SCREENING IN BRAZIL: EXTERNAL ASSESSMENT OF IMPROVING ACCESS AND QUALITY PROGRAM Mara Rejane Barroso Barcelos, Rita de Cássia Duarte Lima, Elaine Tomasi, Bruno Nunes, Suele Manjourany Silva Duro, Malgorzata Chalupowski , Timothy Rebbeck, Luiz Augusto Facchini

31.Caregiver burden and risk of epithelial ovarian cancer in the Nurses’ Health Studies Mollie E. Barnard, Tianyi Huang, Elizabeth M. Poole, Laura D. Kubzansky, Shelley S. Tworoger

32.Air pollution at breast cancer diagnosis and survival from breast cancer Natalie DuPre SM, Jaime E Hart ScD, Kimberly Bertrand ScD, Francine Laden ScD, Rulla Tamimi ScD 33.Altered Progenitor Function and Breast Cancer Predisposition Mihriban Karaayvaz, Kenneth Ross, Leif W. Ellisen

34.Breast cancer knowledge, behaviors, and preferences in Malawi: implications for early detection Racquel E. Kohler, PhD; Satish Gopal, MD MPH; Clara N. Lee, MD MPP; Bryan J. Weiner, PhD; Bryce B. Reeve, PhD; Stephanie B. Wheeler, PhD MPH

35.Circulating Lipids and Mammographic Density Sarah Lucht, Heather Eliassen, Rulla Tamimi

36.Pre- and post-diagnosis analgesic use and ovarian cancer survival Melissa A. Merritt, Megan S. Rice, Shelley S. Tworoger, and Elizabeth M. Poole

37.Texture variation on a mammogram and risk of breast cancer Megan Rice, Kimberly Bertrand, John Heine, Bernard Rosner, Rulla Tamimi

38.Single-cell analysis using CyTOF and DNA-Exchange-Imaging Ron C.J. Schackmann, Jesse L. Silverberg, Sarit S. Agasti, Yu Wang, Peng Yin, Joan S. Brugge

39.Mammography Decision-Making: Trends, Predictors and Effects of Provider Communication in the Health Information National Trends Survey 2011-2014 Laura Spring, MD, Megan Marshall BS, and Erica T. Warner, ScD

40.Sleep duration and difficulty in relation to breast cancer survival: Results from the Nurses’ Health Study Claudia Trudel-Fitzgerald, PhD; Eric S. Zhou, PhD; Elizabeth M. Poole, PhD; Xuehong Zhang, MD, ScD; Shelley S. Tworoger, PhD; Eva Schernhammer, MD, DrPH

41.Rotating Night Shift Work and Mammographic Breast Density in Premenopausal and Postmenopausal Women in the Nurses’ Health Studies Wegrzyn LR, Rosner BA, Tamimi RM, Schernhammer ES

TUMOR BIOLOGY

42.miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple Negative Breast Cancer Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, and Slack FJ

43.Innovative therapeutic strategy to eradicate cancer stem cells and to prevent OvCa recurrence Chiara Bellio, Rosemary Foster, Whitfield B. Growdon and Bo R. Rueda 44.The dual roles of microRNA-200: From inclusion cyst formation to cell migration. Pui Wah Choi, Junzheng Yang, Wing Ping Fong, Ross S. Berkowitz, William R. Welch, Gregory J. Goodall, Shu-Wing Ng

45.CDK4/6 inhibition sensitizes HER2-positive breast cancers to anti-HER2 therapy Shom Goel, April C. Watt, Qi Wang, Sara M. Tolaney, Deborah A. Dillon, Wei Li, Haluk Yuzugullu, X. Shirley Liu, Piotr Sicinski, Eric P. Winer, Ian E. Krop, Jean J. Zhao

46.Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis Jennifer L. Guerriero, Alaba Sotayo, Holly E. Ponichtera, Alexandra Pourzia, Sara Schad, Ruben D. Carrasco, Suzan Lazo, Roderick T. Bronson, Anthony Letai

47.Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin cytoskeleton Hai Hu, Ashish Juvekar, Costas A. Lyssiotis, Evan C. Lien, John G. Albeck, Doogie Oh, Gopal Varma, Yin Pun Hung, Soumya Ullas, Josh Lauring, Pankaj Seth, Mark R. Lundquist, Dean R. Tolan, Aaron K. Grant, Daniel J. Needleman, John M. Asara, Lewis C. Cantley and Gerburg M. Wulf

48.A Role for FANCD2 in Fork Stability and Alternative End-Joining Zeina Kais, Beatrice Rondinelli, Amie Holmes, Colin O'Leary, David Kozono, Alan D. D'Andrea and Raphael Ceccaldi

49.Estrogen receptor-negative breast cancer cell lines exhibit hypersensitivity to the CHK1 inhibitor LY2606368 Jean-Bernard Lazaro, Elizaveta Reznichenko, Kalindi Parmar, Geoffrey I. Shapiro, Alan D. D’Andrea

50.MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism which mimics the role of activated RAS in cancers Manish Neupane, Allison P. Clark, Serena Landini, Nicolai J. Birkbak, Aron C. Eklund, Elgene Lim, Aedin C. Culhane, William T. Barry, Steven E. Schumacher, Rameen Beroukhim, Zoltan Szallasi, Marc Vidal, David E. Hill, Daniel P. Silver

51.Cellular Origin for Epithelial Ovarian Cancer Eun-Sil Park and Zhe Li

52.Sentinel lymph node metastases in breast cancer: A contributor to distant metastases? Ethel R. Pereira, Dmitriy Kedrin, Dennis Jones, Elizabeth Beech, Alphonse G. Taghian and Timothy P. Padera 53.Deciphering the alterations of the ER cistrome with the acquisition of tamoxifen resistance Matthew Pun, Macintosh Cornwell, Myles Brown, Rinath Jeselsohn

54.Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen sialyl Tn K. Starbuck, D. Eavarone, J. Prendergast, A.P.G. da Silva, J. DeSander, J. Behrens2, B. Rueda, R. Foster

55.The Jak/STAT3 signaling pathway promotes 3D growth of ovarian cancer Sarah R. Walker, Yixi Zhang, Suhu Liu, and David A. Frank

56.BRCA1 suppresses tandem duplications at Tus/Ter-stalled replication forks. Nicholas A. Willis, Richard L. Frock, Frederick W. Alt, Ralph Scully

57.Distinct EMT Programs Control Normal Stem Cells and Cancer Stem Cells of Mammary Tissue Xin Ye, Wai Leong Tam, Tsukasa Shibue, Yasemin Kaygusuz, Ferenc Reinhardt, and Robert A. Weinberg1

58. Pinin Interacts with C-terminal Binding Proteins for RNA Alternative Splicing and Epithelial Cell Identity of Human Ovarian Cancer Cells Yanli Zhang, Jamie Sui-Lam Kwok, Pui-Wah Choi, Minghua Liu, Junzheng Yang, Margit Singh, Shu-Kay Ng, William R. Welch, Michael G. Muto, Stephen KW Tsui, Stephen P. Sugrue, Ross S. Berkowitz, and Shu-Wing Ng